Charles Schwab’s ADMA Biologics ADMA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $17.5M | Sell |
2,092,594
-3,178
| -0.2% | -$29K | ﹤0.01% | 1899 |
|
|
2026
Q1 | $18.9M | Sell |
2,095,772
-161,936
| -7% | -$2.56M | ﹤0.01% | 1774 |
|
|
2025
Q4 | $41.2M | Sell |
2,257,708
-103,057
| -4% | -$1.74M | 0.01% | 1276 |
|
|
2025
Q3 | $34.6M | Sell |
2,360,765
-141,261
| -6% | -$2.42M | 0.01% | 1386 |
|
|
2025
Q2 | $45.6M | Buy |
2,502,026
+40,021
| +2% | +$816K | 0.01% | 1161 |
|
|
2025
Q1 | $48.8M | Buy |
2,462,005
+21,711
| +0.9% | +$375K | 0.01% | 1085 |
|
|
2024
Q4 | $41.9M | Buy |
2,440,294
+38,761
| +2% | +$729K | 0.01% | 1254 |
|
|
2024
Q3 | $48M | Buy |
2,401,533
+249,412
| +12% | +$3.88M | 0.01% | 1150 |
|
|
2024
Q2 | $24.1M | Buy |
2,152,121
+377,001
| +21% | +$3.16M | ﹤0.01% | 1554 |
|
|
2024
Q1 | $11.7M | Buy |
1,775,120
+138,417
| +8% | +$757K | ﹤0.01% | 1908 |
|
|
2023
Q4 | $7.4M | Buy |
1,636,703
+27,357
| +2% | +$101K | ﹤0.01% | 2148 |
|
|
2023
Q3 | $5.76M | Buy |
1,609,346
+1,039,893
| +183% | +$4M | ﹤0.01% | 2192 |
|
|
2023
Q2 | $2.1M | Buy |
569,453
+7,231
| +1% | +$26.8K | ﹤0.01% | 2535 |
|
|
2023
Q1 | $1.86M | Buy |
562,222
+76,212
| +16% | +$263K | ﹤0.01% | 2544 |
|
|
2022
Q4 | $1.89M | Buy |
486,010
+7,798
| +2% | +$24.1K | ﹤0.01% | 2589 |
|
|
2022
Q3 | $1.16M | Buy |
478,212
+639
| +0.1% | +$1.53K | ﹤0.01% | 2741 |
|
|
2022
Q2 | $946K | Buy |
477,573
+408,346
| +590% | +$803K | ﹤0.01% | 2820 |
|
|
2022
Q1 | $127K | Hold |
69,227
| – | – | ﹤0.01% | 3382 |
|
|
2021
Q4 | $98K | Buy |
+69,227
| New | +$91K | ﹤0.01% | 3438 |
|
|
2021
Q3 | – | Sell |
-58,927
| Closed | -$95K | – | 3500 |
|
|
2021
Q2 | $95K | Sell |
58,927
-118,327
| -67% | -$208K | ﹤0.01% | 3295 |
|
|
2021
Q1 | $312K | Buy |
177,254
+20,247
| +13% | +$46.3K | ﹤0.01% | 3229 |
|
|
2020
Q4 | $307K | Buy |
157,007
+12,077
| +8% | +$25.4K | ﹤0.01% | 3154 |
|
|
2020
Q3 | $347K | Sell |
144,930
-8,697
| -6% | -$23.8K | ﹤0.01% | 2984 |
|
|
2020
Q2 | $451K | Sell |
153,627
-19,627
| -11% | -$56.4K | ﹤0.01% | 2876 |
|
|
2020
Q1 | $499K | Buy |
173,254
+59,420
| +52% | +$205K | ﹤0.01% | 2715 |
|
|
2019
Q4 | $456K | Hold |
113,834
| – | – | ﹤0.01% | 2852 |
|
|
2019
Q3 | $507K | Buy |
113,834
+48,654
| +75% | +$203K | ﹤0.01% | 2796 |
|
|
2019
Q2 | $253K | Buy |
65,180
+21,480
| +49% | +$94.8K | ﹤0.01% | 3055 |
|
|
2019
Q1 | $166K | Hold |
43,700
| – | – | ﹤0.01% | 3047 |
|
|
2018
Q4 | $105K | Hold |
43,700
| – | – | ﹤0.01% | 3086 |
|
|
2018
Q3 | $272K | Buy |
43,700
+8,300
| +23% | +$47.8K | ﹤0.01% | 3024 |
|
|
2018
Q2 | $160K | Buy |
+35,400
| New | +$176K | ﹤0.01% | 3084 |
|
Other funds holding ADMA
RCMNY
CP
Charles Schwab's ADMA Position: Q2 2026 in Review
Charles Schwab reduced its ADMA Biologics (ADMA) stake by 0.15% in Q2 2026, selling an estimated $29K and leaving 2,092,594 shares worth $17.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1899.
Charles Schwab first reported a position in ADMA in Q2 2018 and has held it in 32 quarters since. The position peaked at $48.8M in Q1 2025. 323 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.
- Charles Schwab held 2,092,594 shares of ADMA Biologics worth $17.5M as of Q2 2026.
- Charles Schwab sold 3,178 ADMA Biologics shares in Q2 2026, an estimated $29K.
- ADMA Biologics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #1899 holding.
- Charles Schwab first reported a position in ADMA Biologics in Q2 2018 and has held it in 32 quarters since.
- Charles Schwab's ADMA Biologics position peaked at $48.8M in Q1 2025.
- 323 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.